Status:
TERMINATED
Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
Lead Sponsor:
Corcept Therapeutics
Conditions:
Hypercortisolism
Cushing Syndrome
Eligibility:
All Genders
Up to 21 years
Brief Summary
This retrospective, multi-center, chart review study will collect patient data from medical charts of pediatric patients who have been treated with Korlym for Cushing's syndrome.
Detailed Description
This retrospective chart review study seeks to collect data from pediatric patients treated with Korlym (mifepristone) to help provide clinicians with some insight on the potential role of mifepriston...
Eligibility Criteria
Inclusion
- Pediatrics (age≤21 years) at time Korlym initiation
- Considered to have a diagnosis of endogenous Cushing's syndrome by the healthcare provider
- Received at least one dose of Korlym
- Availability of pre-treatment (baseline) and follow-up data
Exclusion
- None
Key Trial Info
Start Date :
September 18 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 12 2018
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT03379363
Start Date
September 18 2017
End Date
February 12 2018
Last Update
July 30 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Corcept Therapeutics
Menlo Park, California, United States, 94025